VivoSim Labs faces Nasdaq minimum bid price deficiency notice, risks delisting if noncompliance persists
VIVS•Nasdaq deficiency notice and compliance timeline
Nasdaq issued a noncompliance notice on Aug. 17, 2026, citing a sub-$1 bid price for 30 consecutive business days.
Shares keep trading on the Nasdaq Capital Market under VIVS, with no immediate impact on listing status.
The compliance deadline is set for Feb. 16, 2027; the stock must close at or above $1 for 10 consecutive business days.
If VivoSim Labs fails to cure the deficiency, the company could face delisting risk, although an additional 180-day extension may be available if eligibility conditions are met.
Options include a shareholder-approved reverse stock split, with a proposed ratio range of 1-for-5 to 1-for-20.
